Daniel G Tanenbaum1, Zachary S Buchwald2, Jaymin Jhaveri1, Eduard Schreibmann1, Jeffrey M Switchenko3, Roshan S Prabhu4, Mudit Chowdhary5, Mustafa Abugideiri1, Neil T Pfister1, Bree Eaton1, Shannon E Kahn1, Jeffrey J Olson6, Hui-Kuo G Shu1, Ian R Crocker1, Walter J Curran1, Kirtesh R Patel7. 1. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. Electronic address: zbuchwa@emory.edu. 3. Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia. 4. Southeast Radiation Oncology Group, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina. 5. Department of Radiation Oncology, Rush University, Chicago, Illinois. 6. Department of Neurosurgery and Winship Cancer Institute, Emory University, Atlanta, Georgia. 7. Department of Therapeutic Radiology, Yale University, New Haven, Connecticut.
Abstract
PURPOSE: Stereotactic radiosurgery (SRS) is increasingly used in the management of patients with resected brain metastases (rBMs). A significant complication of this therapy can be radiation necrosis (RN). Despite radiation therapy dose de-escalation and the delivery of several rather than a single dose fraction, rates of RN after SRS for rBMs remain high. We evaluated the dosimetric parameters associated with radiographic RN for rBMs. METHODS AND MATERIALS: From 2008 to 2016, 55 rBMs at a single institution that were treated postoperatively with 5-fraction linear accelerator-based SRS (25-35 Gy) with minimum 3 months follow-up were evaluated. For each lesion, variables recorded included radiation therapy dose to normal brain, location and magnitude of hotspots, clinical target volume (CTV), and margin size. Hotspot location was stratified as within the tumor bed alone (CTV) or within the planning target volume (PTV) expansion margin volume (PTV minus CTV). Cumulative incidence with competing risks was used to estimate rates of RN and local recurrence. Optimal cut-points predicting for RN for hotspot magnitude based on location were identified via maximization of the log-rank test statistic. RESULTS: Median age for all patients was 58.5 years. For all targets, the median CTV was 17.53 cm3, the median expansion margin to PTV was 2 mm, and the median max hotspot was 111%. At 1 year, cumulative incidence of radiographic RN was 18.2%. Univariate analysis showed that max hotspots with a hazard ratio of 3.28 (P = .045), hotspots within the PTV expansion margin with relative magnitudes of 105%, 110%, and 111%, and an absolute dose of 33.5 Gy predicted for RN (P = .029, P = .04, P = .038, and P = .0488, respectively), but hotspots within the CTV did not. CONCLUSIONS: To our knowledge, this is the first study that investigated dosimetric factors that predict for RN after 5-fraction hypofractionated SRS for rBM. Hotspot location and magnitude appear important for predicting RN risk, thus these parameters should be carefully considered during treatment planning.
PURPOSE: Stereotactic radiosurgery (SRS) is increasingly used in the management of patients with resected brain metastases (rBMs). A significant complication of this therapy can be radiation necrosis (RN). Despite radiation therapy dose de-escalation and the delivery of several rather than a single dose fraction, rates of RN after SRS for rBMs remain high. We evaluated the dosimetric parameters associated with radiographic RN for rBMs. METHODS AND MATERIALS: From 2008 to 2016, 55 rBMs at a single institution that were treated postoperatively with 5-fraction linear accelerator-based SRS (25-35 Gy) with minimum 3 months follow-up were evaluated. For each lesion, variables recorded included radiation therapy dose to normal brain, location and magnitude of hotspots, clinical target volume (CTV), and margin size. Hotspot location was stratified as within the tumor bed alone (CTV) or within the planning target volume (PTV) expansion margin volume (PTV minus CTV). Cumulative incidence with competing risks was used to estimate rates of RN and local recurrence. Optimal cut-points predicting for RN for hotspot magnitude based on location were identified via maximization of the log-rank test statistic. RESULTS: Median age for all patients was 58.5 years. For all targets, the median CTV was 17.53 cm3, the median expansion margin to PTV was 2 mm, and the median max hotspot was 111%. At 1 year, cumulative incidence of radiographic RN was 18.2%. Univariate analysis showed that max hotspots with a hazard ratio of 3.28 (P = .045), hotspots within the PTV expansion margin with relative magnitudes of 105%, 110%, and 111%, and an absolute dose of 33.5 Gy predicted for RN (P = .029, P = .04, P = .038, and P = .0488, respectively), but hotspots within the CTV did not. CONCLUSIONS: To our knowledge, this is the first study that investigated dosimetric factors that predict for RN after 5-fraction hypofractionated SRS for rBM. Hotspot location and magnitude appear important for predicting RN risk, thus these parameters should be carefully considered during treatment planning.
Authors: Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316
Authors: Timothy Korytko; Tomas Radivoyevitch; Valdir Colussi; Barry W Wessels; Kunjan Pillai; Robert J Maciunas; Douglas B Einstein Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-14 Impact factor: 7.038
Authors: Roshan S Prabhu; Anees Dhabaan; William A Hall; Tomi Ogunleye; Ian Crocker; Walter J Curran; Hui-Kuo G Shu Journal: J Neurooncol Date: 2013-02-26 Impact factor: 4.130
Authors: Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-23 Impact factor: 7.038
Authors: Kirtesh R Patel; Stuart H Burri; Anthony L Asher; Ian R Crocker; Robert W Fraser; Chao Zhang; Zhengjia Chen; Shravan Kandula; Jim Zhong; Robert H Press; Jeffery J Olson; Nelson M Oyesiku; Scott D Wait; Walter J Curran; Hui-Kuo G Shu; Roshan S Prabhu Journal: Neurosurgery Date: 2016-08 Impact factor: 4.654
Authors: Jim Zhong; Robert H Press; Jeffrey J Olson; Nelson M Oyesiku; Hui-Kuo G Shu; Bree R Eaton Journal: Neurosurgery Date: 2018-11-01 Impact factor: 4.654
Authors: Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: Basem A Dahshan; Joshua S Weir; Robert P Bice; Paul Renz; Daniel T Cifarelli; Linda Poplawski; Joshua Hack; John A Vargo; Christopher P Cifarelli Journal: Brachytherapy Date: 2021-01-14 Impact factor: 2.362
Authors: Giuseppe Minniti; Maximilian Niyazi; Nicolaus Andratschke; Matthias Guckenberger; Joshua D Palmer; Helen A Shih; Simon S Lo; Scott Soltys; Ivana Russo; Paul D Brown; Claus Belka Journal: Radiat Oncol Date: 2021-04-15 Impact factor: 3.481
Authors: Michael T Milano; Jimm Grimm; Andrzej Niemierko; Scott G Soltys; Vitali Moiseenko; Kristin J Redmond; Ellen Yorke; Arjun Sahgal; Jinyu Xue; Anand Mahadevan; Alexander Muacevic; Lawrence B Marks; Lawrence R Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2020-09-11 Impact factor: 8.013